Oral Drug Delivery Videos

  1. What's In A Combination Product Development Lifecycle? 10/8/2025

    In this segment of the Drug Delivery Leader Live online event, Next-Gen Drug Delivery: Rethinking Routes For New Therapies, Carolyn Dorgan, director of technical services at device design consultancy Suttons Creek, lays out the phases and key activities in the development of a combination product or combination therapy. She underscores the importance of integrated development when merging medicinal product development with delivery device development. 

  2. Bolstering Bowel And Bladder Control With Dignify Therapeutics' Karl Thor 2/6/2025

    In this episode of Sit and Deliver, host Tom von Gunden talks with Chief Scientific Officer Karl Thor of Dignify Therapeutics about providing relief for patients suffering from neurogenic bowel and bladder dysfunction.

  3. 3 Key 'Look Forwards' In Drug Delivery Regulatory 1/12/2026

    In this segment of the Drug Delivery Leader Live online event, Eying The Drug Delivery Regulatory Landscape: The 'Must See' Watch List For 2026, Chief Editor Tom von Gunden invites panelists Fran DeGrazio, Barr Weiner, and Rumi Young to identify and comment on their most important takeaways from their panel conversation. They point to platform thinking, post-market manufacturing, and the representation of combination products in regulatory guidances.

  4. Post-Market Surveillance And Post-Approval Changes For Combination Products 1/12/2026

    In this segment of the Drug Delivery Leader Live online event, Eying The Drug Delivery Regulatory Landscape: The 'Must See' Watch List For 2026, Chief Editor Tom von Gunden asks the panel to comment on post-market regulatory considerations and processes for combination products. Among the topics covered are post-approval changes, design outputs, patient safety, and various regulatory guidances.

  5. PBPK Modeling: Mitigating Absorption Risks In Early Drug Development

    Discover how PBPK models combined with in vitro tools and solubility enhancement expertise can be used to identify and mitigate absorption risks in early drug development.

  6. Nanoparticle Enabled Formulation And Drug Delivery Solutions

    Discover how revolutionary and environmentally sustainable nanoparticle technologies coupled with innovative formulation approaches can address drug solubility issues and add value for patients.

  7. Enabling Oral Delivery Of Biologics With Vivtex's Thomas von Erlach 4/7/2026

    The rapidly expanding demand for biologics-based treatments for chronic, metabolic diseases has spurred a desire for oral administration. Videocast host Tom von Gunden talks with CEO Thomas von Erlach from delivery platform developer Vivtex about using high-throughput screening, advanced computational tools, and formulation technologies to drive higher absorption and bioavailability of peptides and other macromolecules delivered via gastrointestinal routes. 

  8. Solid Form Screening Of Active Pharmaceutical Ingredients

    Explore the role of solid form services in helping meet accelerated timelines of the drug development lifecycle along with examples of robust workflows for fast and thorough solid form screens.

  9. What Types Of Products Are Assessed With A URRA? 12/11/2024

    What types of products in development may need to be assessed in accordance with the FDA’s URRA (Use-Related Risk Analysis) guidance? In this segment of the Drug Delivery Leader Live event Human Factors Risk Analysis: Leveraging URRA And UFMEA Tools, Natalie, Abts, head of human factors engineering at Genentech, describes several common scenarios that illustrate when a URRA approach may or may not be needed.

  10. Improve The Bioavailability Of Poorly Soluble Drugs 3/19/2024

    KinetiSol is a fusion-based, solvent-free process that utilizes frictional and shear energies — in a fraction of the time of other amorphous solid dispersion technologies.